Business Wire Feed
Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types
– Findings in neuroendocrine tumors, kidney cancer, advanced colorectal cancer and other tumors to be presented –ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced presentations for its flagship product, CABOMETYX® (cabozantinib), and its investigational oral more...
Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC
Noetik’s TARIO-2 platform analyzed routine pretreatment H&E images from 113 BOT+BAL-treated patients and identified spatial tumor microenvironment patterns associated with response and survival In a retrospective analysis of refractory MSS metastatic colorectal cancer without active more...
City of Hope Researchers Present Advances in Targeted Therapies, Microbiome Science and Blood Cancers at ASCO 2026
New findings in kidney, liver and prostate cancers reflect the shift toward more personalized, biology-driven treatment.LOS ANGELES--(BUSINESS WIRE)--Researchers from City of Hope®, one of the largest and most advanced cancer research and treatment organizations in more...
Artera Presents Multiple ASCO 2026 Abstracts on Multimodal AI (MMAI) Risk Stratification and Treatment Decisions in Cancer
Validation of MMAI in node-positive HR+ breast cancer to determine chemotherapy benefit Concordance analysis between MMAI and 21-gene Recurrence Score test in breast cancer SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic more...
A2 Biotherapeutics Presents Safety and Efficacy Data from the EVEREST-2 Clinical Study, Including Update on the First Complete Response to CAR T-Cell Therapy in a Patient with Non-Small Cell Lung Cancer
Poster Presentations During the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting provide updates on EVEREST-2 and describe approaches to boost potency and preserve selectivity of TmodTM-based precision cell therapiesCHICAGO--(BUSINESS WIRE)--#ASCO26--A2 Biotherapeutics, Inc. (A2 more...
Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting
In the dose optimization stage of the randomized Phase 2 trial (Duravelo-2), zelenectide pevedotin at its optimal dose in combination with pembrolizumab demonstrated response rates comparable to published data for standard of care (SOC) in more...
BioVigil Appoints Brad Ryba as Chief Technology Officer to Accelerate Innovation and Market Expansion
ANN ARBOR, Mich.--(BUSINESS WIRE)--BioVigil, the market leader in electronic hand hygiene and infection prevention technology, has hired Brad Ryba as the company’s Chief Technology Officer (CTO). Ryba will lead the company’s technology and data strategy, more...
Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026
- Late-breaking VISTAS results demonstrate rapid, sustained, and clinically meaningful reductions in pruritus with volixibat in primary sclerosing cholangitis (PSC) - Late-breaking Phase 2b AZURE-1 results demonstrate efficacy and safety of brelovitug for the treatment more...
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35%PITTSBURGH & CLEVELAND--(BUSINESS WIRE)--#AI--A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research more...
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet more...
ASCO 2026: Bayer to Present New Data Across Oncology Portfolio
Primary results from the Phase II ARACOG (AFT-47) head-to-head trial evaluating NUBEQA® (darolutamide) versus enzalutamide in men with metastatic and non-metastatic castration-resistant prostate cancer (CRPC) or metastatic hormone-sensitive prostate cancer (mHSPC) will be presented more...
Diversified Healthcare Trust to Present at Nareit’s REITweek 2026 Investor Conference on Tuesday, June 2nd
NEWTON, Mass.--(BUSINESS WIRE)--Diversified Healthcare Trust (Nasdaq: DHC) today announced that President and Chief Executive Officer Chris Bilotto and Chief Financial Officer and Treasurer Matthew Brown will be presenting at Nareit’s REITweek 2026 Investor Conference in more...
Reimagine Care Expands AI-Enabled Virtual Oncology Model with Moffitt Cancer Center Following Strong Patient and Clinical Outcomes
Initial phase shows sustained patient engagement, reduced acute care utilization and a scalable approach to delivering continuous cancer care beyond the clinicNASHVILLE, Tenn.--(BUSINESS WIRE)--Reimagine Care today announced the expansion of its AI-enabled virtual oncology care more...
Scribe Therapeutics Achieves Regulatory Clearance to Initiate First-in-Human Clinical Study of STX-1150 for LDL-C Reduction
ALAMEDA, Calif.--(BUSINESS WIRE)--#CRISPR--Scribe Therapeutics, Inc. (Scribe), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, today announced that it has secured clearance more...
Inovalon and Face Rock Enterprises Collaborate to Care for Tribal Health Organizations
Pairing Inovalon’s national-scale data and revenue cycle technology and Face Rock’s deep tribal health expertise to strengthen financial sustainability in underserved tribal communitiesBOWIE, Md.--(BUSINESS WIRE)--Inovalon, a leading provider of data and solutions empowering data-driven healthcare, more...
Ontada Integrates Florida Cancer Specialists & Research Institute Data to Enrich Its Data Ecosystem
Strategic milestone delivers one of the most comprehensive and timely real-world views of community oncology, strengthening Ontada’s portfolio for biopharma partnersBOSTON--(BUSINESS WIRE)--Ontada®, a McKesson business dedicated to real-world oncology data and insights, announced the integration more...
Aramark Healthcare+ Recognized by Modern Healthcare as One of the “Best Places to Work™ in Healthcare” for Third Consecutive Year
PHILADELPHIA--(BUSINESS WIRE)--Aramark Healthcare+ has been named to Modern Healthcare’s “Best Places to Work™ in Healthcare” list for 2026, marking the third consecutive year the organization has earned the recognition. Final rankings will be announced later more...
FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint
Guardant Health’s new FDA-approved liquid biopsy integrates genomic and epigenomic insights to provide a more complete, actionable view of cancer from a simple blood draw Approval strengthens Guardant’s leadership in comprehensive molecular profiling and advances more...
HAYA Therapeutics Announces First Cohort Dosed in Phase 1 Clinical Trial of HTX-001, an Investigational Precision Cellular Reprogramming Therapy for Cardiac Fibrosis
HTX-001 is a first-in-class antisense oligonucleotide designed to downregulate WISPER lncRNA, a driver of fibrosis in the heart Phase 1a/b trial to evaluate the safety and tolerability of HTX-001 in healthy volunteers, followed by patients more...
Surescripts Expands Prior Authorization Automation, Enabling 50% More Prescribers Nationwide to Improve Medication Access for Patients in 2026
Prescribers Helped Save Patients $19.7 Million with Real-Time Prescription Benefit Since JanuaryARLINGTON, Va.--(BUSINESS WIRE)--#HealthIT--Surescripts®, the nation’s leading health intelligence network, released new data illustrating significant impact of solutions, including Prior Authorization Automation and Real-Time Prescription more...
Autobahn Therapeutics Presents New Preclinical Data at ASCP Annual Meeting Demonstrating Elunetirom Drives Robust Bioenergetic and Neuroplastic Improvements in Neuronal Cultures
New preclinical findings demonstrate elunetirom’s direct effects on key gene programs that drive mitochondrial biogenesis, ATP production, and neuroplasticity in neuronal cultures Topline data anticipated from Phase 2 AMPLIFY-BD study in adjunctive bipolar depression in more...
IntraBio Receives Regulatory Authorization to Begin Pivotal Phase III Trial of Levacetylleucine in CACNA1A-Related Disorders Across Participating Regions
Pivotal Phase III trial authorized to proceed in every region where IntraBio submitted regulatory applications: the U.S., U.K., EU, and Switzerland Twelve multinational clinical trial sites are now being activated, with recruitment to begin immediately more...
Leading NCI-Designated Cancer Centers Across the Country Leverage ConcertAI’s CancerLinQ to Support Personalized, Evidence-Based Quality Care
URochester Medicine Wilmot Cancer Institute and UCHealth/University of Colorado Anschutz Cancer Center are among the leading institutions using the platform to drive actionable insights and advance quality initiativesCAMBRIDGE, Mass.--(BUSINESS WIRE)--ConcertAI®, the real‑world healthcare intelligence company more...
Scholar Rock to Present at the 2026 Jefferies Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its more...
Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery
The expanded agreement is one of the first major Pharma-AI collaborations to power large-scale foundation model training with a partner's proprietary experimental data Incyte data will be securely used to train Genesis’ next-generation GEMS AI more...